uniQure (QURE) N.V. announced that the company reached agreement with the U.S. Food and Drug Administration, FDA, on key elements of an Accelerated Approval pathway for AMT-130. As part of uniQure’s Regenerative Medicine Advanced Therapy Type B meeting held in late November, the FDA agreed that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway, avoiding the need for an additional pre-submission study. The FDA also agreed that cUHDRS may be used as an intermediate clinical endpoint and that reductions in neurofilament light chain measured in cerebrospinal fluid may serve as supportive evidence of therapeutic benefit in the application for accelerated approval.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on QURE:
- uniQure Begins Phase I/IIa Trial for AMT-260 Therapy
- uniQure announces first patient dosed in GenTLE Phase I/IIa trial of AMT-260
- uniQure N.V. Reports Q3 2024 Progress and Financials
- uniQure reports Q3 EPS (91c), consensus ($1.01)
- uniQure N.V. (QURE) Q3 Earnings Cheat Sheet
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
